Use of fenbendazole-containing therapeutic diets for mice in experimental cancer therapy studies

Journal of the American Association for Laboratory Animal Science

Volumn 51, Issue 2, 2012, Pages 224-230

  Duan, Qiwen ^a,b   Liu, Yanfeng ^a   Booth, Carmen J ^a   Rockwell, Sara ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FENBENDAZOLE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL CULTURE; CONTROLLED STUDY; DIET THERAPY; FEMALE; METASTASIS; MOUSE; NONHUMAN; RADIATION DOSE; TUMOR VOLUME;

ANIMAL FEED; ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEMATODAL AGENTS; CELL LINE, TUMOR; FEMALE; FENBENDAZOLE; MAMMARY NEOPLASMS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; OXYURIASIS; RODENT DISEASES;

ENTEROBIUS VERMICULARIS; MUS; RODENTIA;

EID: 84859149741     PISSN: 15596109     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Biedermann KA, Sung J, Giaccia AJ, Tosto LM, Brown JM. 1991. SCID mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair. Proc Natl Acad Sci USA 88:1394-1397.
2. Cai Y, Zhou J, Webb DC. 2009. Treatment of mice with fenbendazole attenuates allergic airways inflammation and Th2 cytokine production in a model of asthma. Immunol Cell Biol 87:623-629.
3. Chung I, Barrows C, Wilson A, Rummel N, Badaruddin S, Mizokami A, Banyard J, Zetter B. [Internet]. 2010. Benzimidazole as novel therapeutic agent for metastatic prostate cancer. [Cited 01 November 2011]. Available at: http://www. abstractsonline.com/Plan/ViewAbstract.aspx?sKey=94285e5c- 4f3a-49b4-8641- 03cf9a804f77&cKey=fa44601a-4893-4f23-9039- -6c017cbc23b5&mKey= %7b0591FA3B-AFEF-49D2-8E65- 55F41EE8117E%7d.
4. Cray C, Villar D, Zaias J, Altman NH. 2008. Effects of fenbendazole on routine immune response parameters in BALB/c mice. J Am Assoc Lab Anim Sci 47:32-36.
5. Dawson PJ, Gutteridge WE, Gull K. 1984. A comparison of the interaction of antihelminth benzimidazoles with tubulin isolated from mammalian tissue and the parasitic nematode Ascaridia galli. Biochem Pharmacol 33:1069-1074.
6. Düwel D. 1977. Fenbendazole. II. Biological properties and activity. Pesticide Sci 8:550-555.
7. Franke DDH, Shirwan H. 2006. Prophylactic fenbendazole therapy does not affect the incidence and onset of type 1 diabetes in nonobese diabetic mice. Int Immunol 18:453-458.
8. Gadad BS, Daher JPL, Hutchinson EK, Brayton CF, Dawson TM, Plentnikov MV, Watson J. 2010. Effect of fenbendazole on 3 behavioral tests in male C57BL/6N mice. J Am Assoc Lab Anim Sci 49:821-825.
9. Gao P, Dang CV, Watson J. 2008. Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. J Am Assoc Lab Anim Sci 47:37-40.
10. Gupta RP, Larroquette CA, Agrawal KC. 1982. Potential radiosensitizing agents. 5. 2-substituted benzimidazole derivatives. J Med Chem 25:1342-1346.
11. Hall EJ, Giaccia AJ. 2006. Radiobiology for the radiologist, 6th ed. Philadelphia (PA): Lippincott, Williams and Wilkins
12. Harkness JE, Wagner JE. 1995. Specific diseases and conditions, p 171-321. In: The biology and medicine of rabbits and rodents, 4th ed. Media (PA): Williams and Wilkins
13. Institute for Laboratory Animal Research. 1996. Guide for the care and use of laboratory animals. Washington (DC): National Academies Press.
14. Kallman RF, editor. 1987. Rodent tumors models in experimental cancer therapy. New York (NY): Plenum Press.
15. Keller WC. Fenbendazole. (WHO Food Additive Series 29). [Cited 30 June 2011]. Available at www.inchem.org/documents/jecfa/ jecmono/v29je04.htm
16. Lacey E. 1988. The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol 18:885-936.
17. Landin AM, Frasca D, Zaias J, Van der Put E, Riley RL, Altman NH, Blomberg BB. 2009. Effects of fenbendazole on the murine humoral immune system. J Am Assoc Lab Anim Sci 48:251-257.
18. Merino G, Jonker JW, Wagenaar E, Pulido MM, Alvarez AI, Schinkel AH. 2005. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos 33:614-618.
19. Overgaard J. 2007. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25:4066-4074.
20. Percy DH, Barthold SW. 2007. Mice, p 3-95. In: Pathology of laboratory rodents and rabbits, 3rd ed. Ames (IA): Blackwell Publishing.
21. Prichard RK, Kelly JD, Bolin TD, Duncombe VM, Fagan MR. 1981. The effect of iron and protein deficiency on plasma levels and parasite uptake of [14C]fenbendazole in rats infected with Nippostrongylus brasiliensis. Aust J Exp Biol Med Sci 59:567-573.
22. Pritchett KR, Johnson NA. 2002. A review of treatments for the eradication of pinworm infections from laboratory rodent colonies. Contemp Top Lab Anim Sci 41:36-46.
23. Ramp AA, Hall C, Orian JM. 2010. Strain-related effects of fenbendazole treatment on murine experimental autoimmune encephalomyelitis. Lab Anim 44:271-273.
24. Rockwell S. 1972. In vivo-in vitro tumor systems: new models for studying the response of tumors to therapy. Lab Anim Sci 27:831-851.
25. Rockwell S. 1983. Hypoxic cells as targets for cancer chemotherapy, p 157-172. In: Cheng YC, Goz B, Minkoff M. Development of targeted-oriented anticancer drugs. New York (NY): Raven Press.
26. Rockwell S. 1992. Use of hypoxia-directed drugs in the therapy of solid tumors. Semin Oncol 19:29-40.
27. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. 2009. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 9:442-458.
28. Rockwell SC, Kallman RF, Fajardo LF. 1972. Characteristics of a serially transplanted mouse mammary tumor and its tissueculture- adapted derivative. J Natl Cancer Inst 49:735-749.
29. Rockwell S, Liu Y, Higgins SA. 2005. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat 90:233-239.
30. Rockwell S, Liu Y, Seow HA, Ishiguro K, Baumann RP, Penketh PG, Shyam K, Glazer PM, Sartorelli AC. 2011. Preclinical evaluation of laromustine for use in combination with radiation therapy in the treatment of solid tumors. Int J Radiat Biol [Epub ahead of print].
31. Rockwell S, Rockwell KR. 2008. Mouse models for experimental cancer therapy, p 623-630. In: Conn PM, editor. Source book of models for biomedical research. Totowa (NJ): Humana Press.
32. Seaton A, Higgins C, Mann J, Baron A, Bailly C, Neidle S, van den Berg H. 2003. Mechanistic and antiproliferative studies of 2 novel, biologically-active bis-benzimidazoles. Eur J Cancer 39:2548-2555.
33. Seow HA, Penketh PG, Shyam K, Rockwell S, Sartorelli AC. 2005. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl) ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells. Proc Natl Acad Sci USA 102:9282-9287.
34. Soderlind K-J, Gorodetsky B, Singh AK, Bacher NR, Miller GG, Lown JW. 1999. Bis-benzimidazole anticancer agents: targeting human tumor helicases. Anticancer Drug Des 14:19-36.
35. Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, Di Meo A, Boss J, Ashall I, Zavareh RB, Fine N, Simpson CD, Sharmeen S, Rottapel R, Schimmer AD. 2010. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 115:4824-4833.
36. Tannock IF, Hill RP, Bristow RG and Harrington L. 2005. The basic science of oncology, 4th ed. New York (NY): McGraw Hill.
37. Villar D, Cray C, Zaias J, Altman NH. 2007. Biological effects of fenbendazole in rats and mice: a review. J Am Assoc Lab Anim Sci 46:8-15.